PapersFlow Research Brief
Botulinum Toxin and Related Neurological Disorders
Research Guide
What is Botulinum Toxin and Related Neurological Disorders?
Botulinum Toxin and Related Neurological Disorders is a research cluster examining the therapeutic application of Botulinum Toxin in neurology for conditions such as spasticity, stroke complications, pain management, and other neurological disorders, including its mechanisms of action, protein receptors, and toxicology.
This field encompasses 80,096 published works on Botulinum Toxin applications in treating spasticity, stroke-related issues, and pain in neurological contexts. Studies detail mechanisms like protein receptor interactions and toxicology alongside clinical uses in muscle mechanics and neurotoxin effects. Research scales and models, such as those for tactile allodynia and muscle spasticity, support evaluation of these treatments.
Topic Hierarchy
Research Sub-Topics
Botulinum Toxin in Spasticity Management
This sub-topic examines the clinical efficacy, dosing protocols, and long-term outcomes of Botulinum Toxin injections for treating upper and lower limb spasticity in conditions like cerebral palsy and multiple sclerosis. Researchers study injection techniques, muscle selection, and combination therapies with rehabilitation.
Botulinum Toxin for Post-Stroke Hemiplegia
This area focuses on the use of Botulinum Toxin to reduce spasticity and improve motor function in stroke survivors with hemiplegic gait patterns and upper limb impairments. Studies investigate timing of injections, functional recovery metrics, and integration with physiotherapy.
Neuropathic Pain Treatment with Botulinum Toxin
Researchers explore the analgesic mechanisms of Botulinum Toxin in peripheral and central neuropathic pain models, including trigeminal neuralgia and post-herpetic neuralgia. Investigations cover anti-inflammatory effects, nerve sprouting inhibition, and randomized controlled trials.
Molecular Mechanisms of Botulinum Toxin Action
This sub-topic delves into the toxin's interaction with SNARE proteins, synaptic vesicle release inhibition, and receptor binding specificity across serotypes. Studies employ electrophysiology, crystallography, and animal models to elucidate neuromuscular junction blockade.
Botulinum Toxin Safety and Toxicology
Research assesses systemic spread risks, immunogenicity, antibody formation, and dose-dependent adverse effects like dysphagia or weakness. Long-term safety profiles in chronic neurological conditions are analyzed through pharmacovigilance and epidemiological studies.
Why It Matters
Botulinum Toxin treatments address spasticity in stroke patients, as evaluated by scales like the modified Ashworth scale, where Bohannon and Smith (1987) reported 86.7% interrater agreement in grading elbow flexor spasticity across 30 patients with intracranial lesions. In pain management, Chaplan et al. (1994) developed a quantitative assessment of tactile allodynia in rat paws, enabling precise measurement of hyperalgesia relevant to neurological disorders. Fugl-Meyer et al. (1975) provided a cumulative scoring system for motor function and balance in hemiplegic post-stroke patients, followed longitudinally for one year, aiding clinical trials for Botulinum Toxin efficacy. Bennett and Xie (1988) modeled peripheral mononeuropathy in rats producing human-like pain disorders, supporting toxin-based interventions. These tools underpin applications in stroke recovery, Parkinson's disease management as reviewed by Poewe et al. (2017), and neuropathic pain diagnostics per Treede et al. (2007).
Reading Guide
Where to Start
"Interrater Reliability of a Modified Ashworth Scale of Muscle Spasticity" by Bohannon and Smith (1987), as it provides a foundational, highly reliable (86.7% agreement) clinical tool for assessing spasticity directly relevant to Botulinum Toxin treatments in neurology.
Key Papers Explained
Bohannon and Smith (1987) establish spasticity measurement basics, which Fugl-Meyer et al. (1975) extend to comprehensive post-stroke hemiplegic evaluation using cumulative scores tracked over a year. Brott et al. (1989) complement this with a reliable acute stroke scale (kappa 0.66-0.77), while Chaplan et al. (1994) and Bennett and Xie (1988) provide preclinical pain models—rat paw allodynia and mononeuropathy—linking to clinical applications. Poewe et al. (2017) synthesize these into Parkinson's context, and Treede et al. (2007) define neuropathic pain frameworks underpinning toxin therapies.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research sustains focus on spasticity, stroke, and pain models without recent preprints or news. Frontiers involve refining scales like those from Brott et al. (1989) and Bohannon and Smith (1987) for Botulinum Toxin trials in ongoing neurological disorders, including Parkinson's per Poewe et al. (2017).
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Quantitative assessment of tactile allodynia in the rat paw | 1994 | Journal of Neuroscienc... | 7.7K | ✕ |
| 2 | Measurements of acute cerebral infarction: a clinical examinat... | 1989 | Stroke | 5.7K | ✕ |
| 3 | The post-stroke hemiplegic patient. 1. a method for evaluation... | 1975 | Journal of Rehabilitat... | 5.4K | ✓ |
| 4 | A peripheral mononeuropathy in rat that produces disorders of ... | 1988 | Pain | 5.3K | ✕ |
| 5 | Interrater Reliability of a Modified Ashworth Scale of Muscle ... | 1987 | Physical Therapy | 5.3K | ✕ |
| 6 | Parkinson disease | 2017 | Nature Reviews Disease... | 4.6K | ✕ |
| 7 | Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) f... | 2014 | Journal of Oral & Faci... | 4.1K | ✓ |
| 8 | Isolated Hand Paresis: A Case Series | 2013 | Cerebrovascular Diseas... | 4.1K | ✓ |
| 9 | Stages in the development of Parkinson’s disease-related patho... | 2004 | Cell and Tissue Research | 2.7K | ✕ |
| 10 | Neuropathic pain | 2007 | Neurology | 2.6K | ✕ |
Frequently Asked Questions
What is the modified Ashworth scale used for in spasticity assessment?
The modified Ashworth scale grades elbow flexor muscle spasticity in patients with intracranial lesions. Bohannon and Smith (1987) found interrater reliability at 86.7% agreement across 30 patients. It supports clinical evaluation in Botulinum Toxin treatments for neurological spasticity.
How is tactile allodynia quantitatively assessed?
Chaplan et al. (1994) developed a method for quantitative assessment of tactile allodynia in the rat paw. This technique measures pain responses relevant to neurological disorders treated with Botulinum Toxin. It has received 7666 citations for its role in pain research.
What methods evaluate physical performance in post-stroke hemiplegic patients?
Fugl-Meyer et al. (1975) described a cumulative numerical score system for motor function, balance, sensation, and joint function in hemiplegic patients. Patients were followed from one week post-stroke through one year. This aids Botulinum Toxin applications in stroke recovery.
How is neuropathic pain defined in neurological contexts?
Treede et al. (2007) define neuropathic pain as arising from nervous system activity without adequate peripheral stimulation. It results from tissue-damaging stimuli or central generation. This framework guides Botulinum Toxin use in pain management.
What is the reliability of the NIH stroke scale?
Brott et al. (1989) designed a 15-item neurologic examination scale for acute stroke trials with mean interrater kappa of 0.69 and test-retest kappa of 0.66-0.77 in 24 patients. It supports assessments in stroke-related disorders treatable by Botulinum Toxin.
What animal model simulates human pain disorders for Botulinum Toxin research?
Bennett and Xie (1988) produced peripheral mononeuropathy in rats via sciatic nerve ligatures, inducing hyperalgesia, allodynia, and dysesthesia. This mirrors human pain sensations in neurological conditions. It facilitates preclinical testing of toxin therapies.
Open Research Questions
- ? How does Botulinum Toxin interaction with specific protein receptors modulate spasticity in stroke patients beyond current scales like modified Ashworth?
- ? What toxicological thresholds limit Botulinum Toxin dosing in chronic pain management models like rat mononeuropathy?
- ? Can Botulinum Toxin halt progression of Parkinson's-related pathology stages as mapped by Braak et al. (2004)?
- ? Which muscle mechanics changes occur post-Botulinum Toxin in hemiplegic patients evaluated by Fugl-Meyer metrics?
- ? How do receptor binding mechanisms of Botulinum Toxin differentiate its effects in neuropathic versus inflammatory pain?
Recent Trends
The field holds steady at 80,096 works with no 5-year growth data reported.
Highly cited papers from 1975-2017, such as Fugl-Meyer et al. (5396 citations) and Poewe et al. (4605 citations), continue dominating, indicating reliance on established stroke, spasticity, and pain assessment methods.
No recent preprints or news signal shifts.
Research Botulinum Toxin and Related Neurological Disorders with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Botulinum Toxin and Related Neurological Disorders with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers